Cannabis stocks surge after Trump endorses cannabidiol for senior healthcare

U.S. cannabis stocks, including Canopy Growth and Tilray Brands, surged nearly 20% after former President Trump advocated for CBD in senior healthcare and signaled potential marijuana reclassification. Such a move, following the Biden administration's recommendation to move marijuana to Schedule III, would significantly impact the sector by removing the burdensome Section 280E tax code, potentially attracting institutional investors, and narrowing the federal-state regulatory divide, despite the industry's inherent volatility.

Analysis

The U.S. cannabis sector is experiencing a significant, sentiment-driven rally following supportive comments from former President Donald Trump regarding cannabidiol (CBD) and the potential reclassification of marijuana. This catalyst prompted sharp premarket gains, with U.S.-listed shares of Canopy Growth and Tilray Brands jumping nearly 20% and the AdvisorShares Pure U.S. Cannabis ETF (MSOS) surging over 25%. This political signal reinforces the ongoing regulatory momentum initiated by the Biden administration, which has already seen the Department of Health and Human Services recommend moving marijuana from a Schedule I to a Schedule III substance. The primary financial implication of such a reclassification would be the elimination of the 280E tax code burden, which currently prohibits cannabis companies from taking standard business deductions, thereby severely impacting profitability. Resolving this tax barrier is seen as a crucial step that could unlock institutional investment and facilitate listings on major U.S. exchanges. Despite the optimism, the article underscores the sector's inherent volatility, noting the divergent year-to-date performance of stocks like Canopy Growth, which has lost half its value, against gains of over 30% for Cronos and SNDL, highlighting that any regulatory action remains a prolonged process with an uncertain final outcome.

Key Decisions for Investors

• Investors should recognize that bipartisan political momentum for marijuana reclassification represents a potentially transformative catalyst for the sector, with the removal of the 280E tax provision being the most direct driver for improved fundamentals and profitability.
• Consider prioritizing exposure to U.S.-focused cannabis operators and ETFs, such as MSOS, as they stand to benefit most directly from changes in U.S. federal law, including tax relief and a potential pathway to listing on major exchanges.
• While the outlook has improved, it is critical to monitor specific regulatory milestones from federal agencies regarding the confirmation of reclassification and remain prepared for the high volatility that has historically characterized cannabis equities.